With a new HQ under construction and AbbVie as a partner, Alector grabs $133M round to fund a move into the clinic
When Sabah Oney joined Alector three years ago, the two-year-old company helmed by CEO Arnon Rosenthal had a lean, 15-staffer operation tightly packed into one small space.
Today, it’s 65 people — headed to 90 by the end of the year — and the chief business officer can look forward to much more space with a new and expansive 100,000-square foot HQ under construction in South San Francisco.
So as the company positions its first three drugs for neurodegenerative diseases to enter human studies for the first time, this is a great time for a $133 million Series E mega-round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.